Observational studyBMC cardiovascular disorders2025
In-hospital outcomes of percutaneous coronary intervention in acute coronary syndrome patients with heart failure: a real-world observational study from the CCC-ACS registry.
Observational study in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02306616 (Improving Care for Cardiovascular Disease in China), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Improving Care for Cardiovascular Disease in China: A Collaborative Project of AHA and CSC (CCC Project) - Acute Coronary Syndrome
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Impact of SGLT2 Inhibitors on Clinical Outcomes in Patients with Diabetes Mellitus Following Heart Transplantation: A Meta-analysis.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute coronary syndrome (ACS) is a leading cause of heart failure (HF). However, the association between percutaneous coronary intervention (PCI) and in-hospital outcomes among ACS patients with varying degrees of left ventricular ejection fraction (LVEF) and HF remains unclear.
methodsThis prospective nationwide registry study included 4,694 ACS patients with HF (ACS-HF) at admission. Patients were categorized into three subgroups according to LVEF and stratified by PCI receipt during hospitalization. The primary outcome was all-cause death, and the secondary outcome was major adverse cardiovascular and cerebrovascular events (MACCE).
resultsPCI was associated with a lower risk of in-hospital all-cause death (HR, 0.52; 95% CI, 0.38–0.72; P < 0.001) and MACCE (HR, 0.62; 95% CI, 0.48–0.81; P < 0.001) before propensity score matching (PSM), particularly in ACS-HFmrEF and ACS-HFpEF subgroups. After PSM, PCI remained associated with a lower risk of all-cause death (HR, 0.65; 95% CI, 0.45–0.93; P = 0.018) and MACCE (HR, 0.65; 95% CI, 0.48–0.88; P = 0.005) in the overall ACS-HF cohort. However, in ACS-HFrEF patients, the association between PCI and outcomes was not statistically significant for all-cause death (HR, 0.82; 95% CI, 0.47–1.42; P = 0.481) or MACCE (HR, 0.77; 95% CI, 0.48–1.23; P = 0.267).
conclusionIn this large, nationwide registry, PCI was associated with more favorable short-term, in-hospital outcomes in ACS patients with HF, especially among those with preserved or mildly reduced EF. No significant association was observed in ACS-HFrEF patients, highlighting the need for further prospective studies to clarify the underlying mechanisms and long-term impact.
trial registrationClinicalTrials.gov Identifier: NCT02306616.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.